Insight Molecular Diagnostics Inc. Common Stock (IMDX)

Price$5.61

Value ScoreF

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-1.11%

Price vs S&P 500 (4W)-12.83%

VGM Score37.84

Market Capitalization$181.15M

All Metrics

Book Value / Share (Quarterly)$0.04

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)61.65%

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)-33.97%

Gross Margin (TTM)51.31%

Net Profit Margin (TTM)-2454.64%

EPS (TTM)$-1.48

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-1.48

Revenue Growth (5Y)27.15%

EPS (Annual)$-1.65

ROI (Annual)-108.54%

Gross Margin (Annual)56.67%

Net Profit Margin (5Y Avg)-3363.86%

Cash / Share (Quarterly)$0.87

Revenue Growth QoQ (YoY)-98.50%

ROA (Last FY)-194.99%

Revenue Growth TTM (YoY)-49.28%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-110.62%

Operating Margin (TTM)-2500.67%

Cash Flow / Share (Annual)$-0.88

P/B Ratio164.98x

P/B Ratio (Quarterly)787.10x

Net Income / Employee (Annual)$-913,100

EV / Revenue (TTM)78.94x

Net Interest Coverage (TTM)-459.75x

ROA (TTM)-119.13%

EPS Incl Extra (Annual)$-1.65

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)2.42x

3-Month Avg Trading Volume0.29M

52-Week Price Return107.78%

Revenue / Employee (TTM)$35,400

P/S Ratio (Annual)44.67x

Asset Turnover (Annual)0.16x

52-Week High$8.51

Operating Margin (5Y Avg)-2088.66%

EPS Excl Extra (Annual)$-1.65

CapEx CAGR (5Y)20.96%

26-Week Price Return7.06%

Quick Ratio (Annual)1.11x

13-Week Price Return14.72%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.54x

Enterprise Value$153.86M

Revenue / Share Growth (5Y)-18.63%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$73,700

Pretax Margin (Annual)-1238.52%

Cash / Share (Annual)$0.40

3-Month Return Std Dev153.87%

Gross Margin (5Y Avg)37.19%

Net Income / Employee (TTM)$-869,800

ROE (Last FY)-108.54%

Net Interest Coverage (Annual)-463.48x

EPS Basic Excl Extra (Annual)$-1.65

Receivables Turnover (TTM)1.05x

Total Debt / Equity (Quarterly)0.92x

EPS Incl Extra (TTM)$-1.48

Receivables Turnover (Annual)2.96x

ROI (TTM)-374.15%

P/S Ratio (TTM)92.94x

Pretax Margin (5Y Avg)-2091.79%

Revenue / Share (Annual)$0.13

Price vs S&P 500 (52W)84.92%

Year-to-Date Return-25.20%

5-Day Price Return-1.92%

EPS Normalized (Annual)$-1.65

ROA (5Y Avg)-103.60%

Net Profit Margin (Annual)-1238.52%

Month-to-Date Return-9.66%

EBITD / Share (Annual)$-1.61

Operating Margin (Annual)-1260.76%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-106.68%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.48

Inventory Turnover (TTM)2.26x

Pretax Margin (TTM)-2454.64%

Price vs S&P 500 (13W)3.36%

Beta1.80x

Revenue / Share (TTM)$0.06

ROE (TTM)-426.68%

52-Week Low$2.33

vGradeF

gGradeD

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.12est. -0.27

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.90

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	B	$5.61
IDXXIdexx Laboratories Inc	D	B	C	$560.88
LNTHLantheus Holdings, Inc	C	B	B	$104.52
CLDXCelldex Therapeutics, Inc	F	F	B	$31.27
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	D	$15.59
NEOGNeogen Corp	C	C	B	$9.10
NTLAIntellia Therapeutics, Inc	D	C	C	$12.11
QDELQuidelOrtho Corporation Common Stock	C	C	D	$14.13
ACHVAchieve Life Sciences, Inc.	F	F	A	$5.52
MYGNMyriad Genetics Inc	C	C	C	$4.33
TKNOAlpha Teknova, Inc. Common Stock	C	C	C	$4.20

About

Insight Molecular Diagnostics is a molecular diagnostics company that uses donor-derived cell-free DNA (dd-cfDNA) quantification technology for transplant monitoring and related applications. The company markets GraftAssureIQ, a research-use-only test kit, and is developing GraftAssureDx, a clinical-grade product for broader adoption. Its mission is to democratize access to advanced molecular diagnostic testing to improve patient outcomes.